No Detail Found!

New Direct Acting Antiviral Agents for the Treatment of Hepatitis C: 2016 and Beyond.

Author(s)
Muhammad Umar Center for Liver and Digestive Diseases (CLD), Department of Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Tayyab Saeed Akhter Center for Liver and Digestive Diseases (CLD), Department of Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Abstract
Hepatitis C is one of the commonest public health problems with 130 million people infected worldwide and the burden is increasing. Previously, Interferon along with Ribavirin was the mainstay of treatment but it was associated with toxic side effects. An all-oral regimen with higher rates of sustained viral response (SVR), minimal side effects and no restriction for liver fibrosis staging, was long awaited. Several all-oral interferon-free direct acting antiviral agents (DAAs) have now been approved by FDA for different genotypes of HCV. These include Sofosbuvir, Ledipasvir, Daclatasvir, Simeprevir, Dasabuvir, Ombitasvir, Paritaprevir and Ritonavir. These agents are also available in different combinations commercially under various trade names. A number of studies have proved their efficacy and the AASLD and EASL guidelines recommend several options for each genotype in different categories including treatment naïve, relapsers, failure, compensated and decompensated cirrhosis. The purpose of this article is to review the persistently changing treatment regimens for hepatitis C and to simplify the dynamicity of the subject and selection of appropriate regimen for these patients.
Publication Details
Page(s) 843-850
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 26, Issue: 10, Year: 2016

Request the full text from PASTIC

References
HajarizadehB,GrebelyJ,DoreGJ, 2013.Epidemiology and natural history of HCV infection,Nat Rev Gastroenterol Hepatol 10 553 -62
LavanchyD., 2009.The global burden of hepatitis C,Liver Int 29 74 -81
2015.-vs-hepatitisC_testing,Accessed August 14 -
SeeffLB, 2002.Natural history of chronic hepatitis C,Hepatology 36 S35 -46
HamidS,UmarM,AlamA,SiddiquiA,QureshiH,ButtJ. PSG, 2004.consensus statement on management of hepatitis C virus Infection - 2003,J Pak Med Assoc 54 146 -50
PockrosPJ, 2012.Interferon-free hepatitis C therapy: how close are we?,Drugs 72 1825 -31
MannsMP,McHutchisonJG,GordonSC,RustgiVK,ShiffmanM,ReindollarR, 2001.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial,Lancet 358 958 -65
McHutchisonJG,GordonSC,SchiffER,ShiffmanML,LeeWM,RustgiVK, 1998.Interferon alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C,N Engl J Med 339 1485 -92
McHutchisonJG,LawitzEJ,ShiffmanML,MuirAJ,GallerGW,McConeJ, 2009.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection,N Engl J Med 361 580 -93
PoordadF,McConeJ,BaconBR,BrunoS,MannsMP,SulkowskiMS, 2011.Boceprevir for untreated chronic HCV genotype 1 infection,N Engl J Med 364 1195 -206
JacobsonIM,McHutchisonJG,DusheikoG,Di BisceglieAM,ReddyKR,BzowejNH, 2011.Telaprevir for previously untreated chronic hepatitis C virus infection,N Engl J Med 364 2405 -16
2013.,Soldavi US prescribing information -
2013.,Olysio US. prescribing information -
LawitzE,MangiaA,WylesD,Rodriguez-TorresM,HassaneinT,GordonSC, 2013.Sofosbuvir for previously untreated chronic hepatitis C infection,N Engl J Med 368 1878 -87
AASLD-IDSA, 2016.Recommendations for testing, managing,(August 30 -
2015.EASL clinical practice guidelines: Management of hepatitis C virus infection,J Hepatol 63 199 -236
GaneEJ,StedmanCA,HylandRH,DingX,SvarovskaiaE,SymondsWT, 2013.Nucleotide polymerase inhibitor Sofosbuvir plus Ribavirin for hepatitis C,N Engl J Med 368 34 -44
OsinusiA,MeissnerEG,LeeYJ,BonD,HeytensL,NelsonA, 2013.Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial,JAMA 310 804 -11
GaneEJ,StedmanCA,HylandRH,DingX,SvarovskaiaE,SymondsWT, 2013.Nucleotide polymerase inhibitor Sofosbuvir plus Ribavirin for hepatitis C,N Engl J Med 368 34 -44
JacobsonIM,GordonSC,KowdleyKV,YoshidaEM,Rodriguez-TorresM,SulkowskiMS, 2013.POSITRON study; FUSION study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options,N Engl J Med 368 1867 -77
AkhterTS,UmarM,UmarS,NisarG,KhaarHTB,ShehzadA, 2016.Trends of Sofosbuvir treatment for chronic hepatitis C infection in genotype 3 patients: An experience from center for liver and digestive diseases,Pakistan [DDW abstract Su1461] Gastroenterology 150 S1106 -
AfdhalN,ZeuzemS,KwoP,ChojkierM,GitlinN,PuotiM, 2014.Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection,N Engl J Med 370 1889 -98
AfdhalN,ReddyKR,NelsonDR,LawitzE,GordonSC,SchiffE, 2014.Ledipasvir and Sofosbuvir for previously treated HCV genotype 1 infection,N Engl J Med 370 1483 -93
LawitzE,PoordadFF,PangPS,HylandRH,DingX,MoH, .Sofosbuvir and Ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection, -
GaneEJ,StedmanCA,HylandRH,PangPS,DingX,SymondsWT, 2013.All-oral Sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: The ELECTRON study,J Hepatol 58 S6 -S7
GuedjJ,DahariH,RongL,SansoneND,NettlesRE,CotlerSJ, 2013.Modeling shows that NS5A inhibitor Daclatasvir has two modes of action and yields a shorter estimate of hepatitis C virus half life,Proc Natl Acad Sci USA 110 3991 -6
SulkowskiMS,GardinerDF,Rodriguez-TorresM,ReddyKR,HassaneinT,JacobsonI, 2014.Daclatasvir plus Sofosbuvir for previously treated or untreated chronic HCV infection,N Engl J Med 370 211 -21
ChayamaK,SuzukiY,Ikeda K, .All-oral combination of Daclatasvir plus Asunaprevir in interferon-ineligible naive/ intolerant and non-responder Japanese patients chronically infected with HCV genotype 1b: Results from a phase 3 trial. Presented at: The 64th annual meeting of the American Association for the study of liver diseases; November 1-5, -
JacobsonI,DoreGJ,FosterGR,FriedMW,RaduM,RafalskiyVV, 2013.Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial,J Hepatol 58 S574 -
LawitzE,FornsX,ZeuzemS,GaneE,BronowickiJP,AndreoneP, 2014.Simeprevir (TMC435) with Peginterferon/ Ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Results from PROMISE, a phase III trial,Gastroenterology 146 1669 -79
ZeuzemS,BergT,GaneE,FerenciP,FosterGR,FriedMW, 2014.Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial,Gastroenterology 146 430 -41
JacobsonIM,GhalibR,Rodriguez-TorresM., .SVR results of a once-daily regimen of Simeprevir (SMV, TMC435) plus Sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study . 2013 The Liver Meeting, -
PoordadF,SchiffER,VierlingJM, 2015.Ribavirin combination for HCV patients with advanced cirrhosis or posttranspfflt recurrence: Phase 3 ALLY-1 study [EASL abstract LO8],J Hepatol 62 S261 -62
KowdleyKV,LawitzE,PoordadF,CohenDE,NelsonDR,ZeuzemS, 2014.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1,N Engl J Med 370 222 -32
SAPPHIRE-I-,Hepatitis-C-Patients-,- International-, 2015.-SAPPHIRE-IIStudies-in-Chronic-,Accessed August 14 -
FeldJJ,KowdleyKV,CoakleyE,SigalS,NelsonDR,CrawfordD, 2014.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin,N Engl J Med 370 1594 -1603
ZeuzemS,JacobsonIM,BaykalT,MarinhoRT,PoordadF,BourlièreM, 2014.Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin,N Engl J Med 370 1604 -14
FerenciP,BernsteinD,LalezariJ,CohenD,LuoY,CooperC, 2014.Dasabuvir with or without ribavirin for HCV,N Engl J Med 370 1983 -92
LawitzE,GaneE,PearlmanB,TamE, 2015.Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): A randomised, openlabel phase 2 trial,Lancet -
SulkowskiM,HezodeC,GerstoftJ, 2015.Efficacy and safety of 8 weeks versus 12 weeks of treatment with Grazoprevir (MK5172) and Elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): A randomised, open-label phase 2 trial,Lancet -
2016.FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4, -
FeldJJ,JacobsonIM,HézodeC,AsselahT,RuanePJ,GruenerN, 2015.,New Eng J Med 373 2599 -607
FosterGR,AfdhalN,RobertsSK,BräuN,GaneEJ,PiankoS, 2015.Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection,New Eng J Med 373 2608 -17
CurryMP,O'LearyJG,BzowejN,MuirAJ,KorenblatKM,FenkelJM, 2015.Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis,N Eng J Med 373 2618 -28
LangeCM,ZeuzemS. Perspectives, 2013.and challenges of interferon-free therapy for chronic hepatitis C,J Hepatol 58 583 -92
HezodeC,FontaineH,DorivalC,ZoulimF,LarreyD,CanvaV, 2014.Effectiveness of telaprevir or boceprevir in treatmentexperienced patients with HCV genotype 1 infection and cirrhosis,Gastroenterology 147 132 -42
LawitzE,SulkowskiMS,GhalibR,Rodriguez-TorresM,YounossiZM,CorregidorA, 2014.Simeprevir plus Sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study,Lancet 384 1756 -65
BourliereM,BenaliS,AnsaldiC,Le FolgocG,RisoA,LecomteL, 2015.Optimal therapy of genotype-2 chronic hepatitis C: What's new?,Liver Int 35 21 -26
LawitzE,PoordadF,PangPS,HylandRH,DingX,MoH, 2013.Once daily Sofosbuvir/Ledipasvir fixed dose combination with or without ribavirin resulted in ≥ 95% sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: The LONESTAR trial,Hepatology 58 315A -6A
PoordadF,HezodeC,TrinhR,KowdleyKV,ZeuzemS,AgarwalK, 2014.dasabuvir with ribavirin for hepatitis C with cirrhosis,N Engl J Med 370 1973 -82
LawitzE,PoordadF,BrainardDM,HylandRH,AnD,DvorySobolH, 2015.Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis,Hepatology 61 769 -75
ZeuzemS,DusheikoGM,SalupereR,MangiaA,FlisiakR,HylandRH, 2014.Sofosbuvir and ribavirin in HCV genotypes 2 and 3,N Engl J Med 370 1993 -2001
NelsonDR,CooperJN,LalezariJP,LawitzE,PockrosPJ,GitlinN, 2015.All-oral 12-week treatment with Daclatasvir plus Sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study,Hepatology 61 1127 -35
RuanePJ,AinD,StrykerR,MeshrekeyR,SolimanM,WolfePR, 2014.Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry,J Hepatol 62 1040 -6
KapoorR,KohliA,SidharthanS,SimsZ,PetersenTL,OsinusiA, 2014.All oral treatment for genotype 4 chronic hepatitis C infection with Sofosbuvir and Ledipasvir: Interim results from the NIAID SYNERGY trial,Hepatology 60 321A -
AbergelA,Loustaud-RattiV,MetivierS., 2015.Ledipasvir/Sofosbuvir for the treatment of patients with chronic genotype 4 or 5 HCV infection. 50th Annual Meeting of the European Association for the Study of the Liver (EASL),April 22-26 -
GaneEJ,HylandRH,AnD., 2014.High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),November 7-11 -
FlammSL,EversonGT,CharltonM,DenningJM,ArterburnS,Brandt-SarifT, 2014.Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: Preliminary results of a prospective, multicenter study,Hepatology 60 320A -
0

Citations

0

Downloads

81

Views